Akari Therapeutics (CLA1) Ownership - Who Owns Akari Therapeutics?
Akari Therapeutics (CLA1) Ownership Overview
- 17.16% Insiders
- 4.38% Other Institutional Investors
- 78.46% Public Companies and Individual Investors
The ownership structure of Akari Therapeutics (DE:CLA1) stock is a mix of institutional, retail, and individual investors. Approximately 4.38% of the company’s stock is owned by Institutional Investors, 17.16% is owned by Insiders, and 78.46% is owned by Public Companies and Individual Investors.
The ownership structure of Akari Therapeutics (DE:CLA1) stock is a mix of institutional, retail, and individual investors. Approximately 4.38% of the company’s stock is owned by Institutional Investors, 17.16% is owned by Insiders, and 78.46% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Hoyoung Huh | 140,805 | Insider | 6.16% | 9,575 |
| Ray Prudo | 76,861 | Insider | 3.36% | 5,227 |
| Gaslightwala Abizer | 41,173 | Insider | 1.80% | 2,800 |
| Sandip I Patel | 38,877 | Insider | 1.70% | 2,644 |
| James Neal | 36,271 | Insider | 1.59% | 2,466 |
| Kameel D. Farag | 23,309 | Insider | 1.02% | 1,585 |
| Robert Bazemore | 22,759 | Insider | 1.00% | 1,548 |
| Patel Samir Rashmikant | 12,102 | Insider | 0.53% | 823 |
FAQ
Who Owns Akari Therapeutics (DE:CLA1)?
According to the latest TipRanks data, approximately 4.38% of the company's stock is held by institutional investors, 17.16% is held by insiders, and 78.46% is held by public companies and individual investors.
What percentage of Akari Therapeutics (DE:CLA1) stock is held by institutional investors?
According to the latest TipRanks data, approximately 4.38% of Akari Therapeutics (DE:CLA1) stock is held by institutional investors.
What percentage of Akari Therapeutics (DE:CLA1) stock is held by retail investors?
According to the latest TipRanks data, approximately 78.46% of Akari Therapeutics (DE:CLA1) stock is held by public companies and individual investors.
Who owns the most shares of Akari Therapeutics (DE:CLA1)?
Hoyoung Huh owns the most shares of Akari Therapeutics (DE:CLA1).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.